• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Noxafil (posaconazole) Oral Suspension


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

 

Sections Modified Summary of Changes to Contraindications and Warnings

CONTRAINDICATIONS

PRECAUTIONS

  • Information for Patients
  • Drug Interactions
    • Table 8
      • Efavirenz
    • Table 9
      • Sirolimus
      • Atazanavir
      • Ritonavir
    • Table 10
      • Halofantrine
      • Digoxin

PATIENT PACKAGE INSERT

  • Who should not take Noxafil?
    • Sirolimus
  • Can I take other medicines with Noxafil?
    • Ritonavir
    • Atazanavir

CONTRAINDICATIONS

...Co-administration of Noxafil (posaconazole) with sirolimus is contraindicated ...

 

Label approved 05/20/2008 is not available on Drugs@FDA